108 results about "Invasive pituitary adenoma" patented technology

The present compounds are intermediates for the preparation of quinoline derivatives and compositions having gonadotropin-releasing hormone antagonistic activity useful as propylactics or therapeutic agent for the prevention or treatment of several hormone dependent diseases, for example, a sex hormone dependent cancer (e.g. prostatic cancer, uterine or cervical cancer, breast cancer, pituitary adenoma), benign prostatic hypertrophy, myoma of the uterus, endometriosis, precocious puberty, amenorrhea, premenstrual syndrome, polycystic ovary syndrome and acne vulgaris; are effective as a fertility controlling agent in both sexes (e.g. a pregnancy controlling agent and a menstrual cycle controlling agent); can be used as a male or female contraceptive, as an ovulation-inducing agent; can be used as an infertility treating agent by using a rebound effect owing to a stoppage of administration thereof; and are useful for modulating estrous cycles in animals in the field of animal husbandry, as agents for improving the quality of edible meat or promoting the growth of animals, and as agents for promoting spawning in fish.

The invention provides application of specific gene mutation in molecular diagnosis and targeted therapy of pituitary adenoma detection. Specifically, the invention provides a type of specific gene mutations in patients suffering from pituitary adenoma. The experimental result proves that the patients suffering from pituitary adenoma can be diagnosed by detecting the gene mutations.

A gonadotropin-releasing hormone antagonistic composition, which comprises an optionally substituted condensed-bicyclic compound consisting of a homo or hetero 5 to 7 membered ring and a homo or hetero 5 to 7 membered ring is effective as a propylactic or therapeutic agent for the prevention or treatment of several hormone dependent diseases, for example, a sex hormone dependent cancer (e.g. prostatic cancer, cancer of uterine cervix, breast cancer, pituitary adenoma), benign prostatic hypertrophy, myoma of the uterus, endometriosis, precocious puberty, amenorrhea, premenstrual syndrome, polycystic ovary syndrome and acne vulgaris; is effective as a fertility controlling agent in both sexes (e.g. a pregnancy controlling agent and a menstrual cycle controlling agent); can be used as a contraceptive of male or female, as an ovulation-inducing agent of female; can be used as an infertility treating agent by using a rebound effect owing to a stoppage of administration thereof; is useful as modulating estrous cycles in animals in the field of animal husbandry, as an agent fro improving the quality of edible meat or promoting the growth of animals; is useful as an agent of spawning promotion in fish.

Disclosed herein is the treatment of vision loss in a mammal by transplanting an effective amount of hNT-Neuron cells. The treatment can be accomplished by injecting the cells into the retinal area of the eye. Additionally, the cells can be injected into the visual cortex of the brain. Conditions to be treated are vision loss due to optic nerve damage, including glaucoma, optic nerve sheath meningioma and glioma, Graves' ophthalmopathy, benign or malignant orbital tumors, metastatic lesions, tumors arising from the adjacent paranasal sinuses or middle cranial fossa, giant pituitary adenomas, brain tumors or abscesses, cerebral trauma or hemorrhage, meningitis, arachnoidal adhesions, pseudotumor cerebri, cavernous sinus thrombosis, dural sinus thrombosis, encephalitis, space-occupying brain lesions, severe hypertensive disease or pulmonary emphysema.

The invention discloses a use of a biological marker detection reagent in preparing a kit for detecting the invasiveness of pituitary adenomas, and a kit and a biological marker combination for detecting the invasiveness of pituitary adenomas. The invasiveness of pituitary adenomas of a patient can be detected by detecting an expression level of a biological marker, so that the grade malignancy of the pituitary adenomas can be known, and an effective basis can be provided for knowing the prognosis of the pituitary adenomas and instructing the clinical diagnosis and treatment.

The invention discloses an application of a USP8 gene detection object in preparation for ACTH-type pituitary adenoma molecular pathological diagnosis and typing products. The invention provides a kit used for detecting the ACTH-type pituitary adenoma subtypes of a to-be-detected patient with the ACTH-type pituitary adenoma, wherein the kit comprises a comparison card for recording a detection standard and a sequencer. Experiments of the application disclosed by the invention prove that USP8 gene mutation is peculiar in the ACTH-type pituitary adenoma, and does not exist in other types of pituitary adenoma, so that the USP8 gene mutation can be used as a specific molecular pathological diagnosis marker for the ACTH-type pituitary adenoma. The ACTH-type pituitary adenoma can be further divided into two subtypes, namely a mutant type (with the USP8 gene mutation) and a wide type (without the USP8 gene mutation), so that an individualized clinical treatment strategy is adopted in time.

The invention discloses NFIC gene capable of serving as a molecular marker for early diagnosis of pituitary adenomas. Experiments of the invention prove that NFIC gene has significantly improved expression in pituitary adenomas tissues when compared to normal pituitary tissues; RNA interference experiments prove that NFIC can affect the proliferation of pituitary adenomas cells. According to the study results of the invention, it is possible to develop drugs capable of inhibiting NFIC gene expression, thus preventing and treating pituitary adenomas clinically.

The invention belongs to the technical field of biological medicines, relates to novel medicinal applications of dopamine I receptor agonists, and in particular relates to novel applications of the dopamine I receptor agonists in preparing tumor treatment medicines. The dopamine I receptor agonists comprise DRD1 and DRD5 agonists, and are selected from SKF83959 or SKF38393 compounds. The cell culture and drug intervention experiments prove that the dopamine receptor agonist SKF83959 can inhibit the mTOR pathway for inducing autophagy, and increase ROS for prompting the cell death from the in-vitro and in-vivo levels, so that the growth of benign or malignant tumor can be inhibited. The dopamine I receptor agonists SKF83959 and SKF38393 can be used for preparing the medicines for treating tumors, wherein the tumors comprise the benign tumour including pituitary adenoma and the malignant tumors including malignant glioma, colon cancer, liver cancer, stomach cancer and the like.

The invention discloses a molecular marker for diagnosis and treatment of pituitary adenoma. Pituitary adenoma is a common intracranial benign tumor and can induce endocrine symptoms as well as intracranial hypertension and change of vision and view. Experiments prove that the expression of PAEP gene in the pituitary adenoma tissue is up-regulated, and the expression of the PAEP gene can inhibit the proliferation of pituitary adenoma cells and promote the apoptosis of the pituitary adenoma cells. The invention provides a new molecular means for the diagnosis and treatment of pituitary adenoma.

Spiroindoline derivatives, process for their preparation and pharmaceutical compositions thereof, their use for the treatment and / or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and / or prophylaxis of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selected from the group of endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (e.g., assisted reproductive therapy such as in vitro fertilization). The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.

The invention discloses application of a BRAF gene detector to preparation of an ACTH type pituitary adenoma molecular pathological diagnosis and parting product. It is proved through tests that BRAF gene mutation is peculiar to ACTH type pituitary adenoma and not found in other types of pituitary adenoma, so that the BRAF gene mutation can serve as a specific molecular pathological diagnosis marker of the ACTH type pituitary adenoma. According to the result that a BRAF gene is mutant or not, the ACTH pituitary adenoma can be further divided into two subtypes, namely the BRAF mutant type and the wild type, the mean volume of the BRAF mutant type ACTH pituitary adenoma is small, the attack degree is low, and the midnight serum cortisol concentration is less than or equal to 22 ug / dl; the mean volume of the wild type ACTH pituitary adenoma is large, the attack degree is high, and the midnight serum cortisol concentration is greater than 22 ug / dl. Therefore, the different subtypes of the ACTH pituitary adenoma can be judged by detecting whether the BRAF gene is mutant or not, and different clinical treatment strategies are adopted in time accordingly.

The invention provides application of tangeretin in preparation of a medicine for treating functional pituitary adenoma. According to the technical scheme, the tangeretin in the invention is capable of effectively inhibiting cell proliferation of prolactinomas MMQ on a cellular level and presents obvious time dependence and dose dependence. Meanwhile, the tangeretin can achieve effects of obviously inducing apoptosis of MMQ cells, effectively inhibiting tumor growth of tumor-bearing mice on an animal model level and prolonging the life cycle of the tumor-bearing mice. Therefore, due to use ofthe tangeretin, a novel solution is provided for treatment of the prolactinomas.

The invention provides a traditional Chinese medicine composition for treating pituitary adenoma. The traditional Chinese medicine composition comprises raw materials including rice sprouts, ligusticum wallichii, orange peels, radix codonopsis, dendrobe, Chinese angelica, cortex acanthopanacis, poria cocos, radix angelicae, seaweed, Chinese wolfberry fruits, curcuma zedoary, radix bupleuri, leonurus, indian iphigenia bulb, hematoxylon, hairyvein agrimony and the root of kudzu vines. Compared with pure western medicine therapy, the index of the pituitary adenoma can be well reduced, the clinical symptoms of a patient can be decreased, kidney diseases can be prevented from further deteriorating, and the traditional Chinese medicine composition has no toxic and side effects and has high safety and comfort level.

The invention provides the use of a reagent for detecting the expression level of a protein marker in preparing a product for detecting radiotherapy resistance of a pituitary adenoma, as well as a kit and protein marker combination for detecting the radiotherapy resistance of a pituitary adenoma. The present invention can detect the sensitivity of the treated object to radiotherapy of pituitary adenoma by detecting the expression level of protein markers, and analyze whether there is radiotherapy resistance, thereby providing an effective basis for predicting the effect of patients receiving radiotherapy and guiding clinical diagnosis and treatment.

The invention discloses a human pituitary adenoma cell line and application thereof, and belongs to the field of tumor biology. The collection number of human pituitary adenoma cell line (HPA1446) is CGMCC NO.12672. The human pituitary adenoma cell line has the advantages that the cell line can be cultured in vitro for a long time, the cell characteristic is not changed, and the cell line is a powerful tool for related research of pituitary adenoma; the cell line is a powerful tool for studying tumor disease and related molecule action mechanisms, preparing tumor related animal experiment models, studying, screening and evaluating tumor treatment medicines / methods / diagnosis reagents, developing tumor medicine targets and tumor biological treatment new techniques, and detecting study of related biological engineering.

The invention belongs to the technical field of biological medicine and relates to a medicine composition for treating pituitary adenoma, application of the medicine composition, a medicine box and a packaging piece. The medicine composition, the medicine box and the packaging piece contain chloroquine / hydroxychloroquine which serves as a combined preparation and is used simultaneously, separately or sequentially, and a therapeutically effective amount of dopamine receptor agonist, and the dopamine receptor agonist is cabergoline or bromocriptine. When the medicine composition, the medicine box and the packaging piece are used for treating tumors, the medicine effect which is superior to the medicine effect obtained by separately using the cabergoline can be achieved, and the clinical treatment effect is improved.

The present invention relates to C-terminal HSP90 inhibitors, like silibinin, novobiocin and derivatives thereof, stereoisomeric forms, prodrugs, solvates, hydrates and / or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and / or diluents. Said compounds and its compositions have been identified as useful for the treatment of pituitary adenomas such as corticotroph adenomas, lactotroph adenomas, somatotroph adenomas and thyrotroph adenomas.

The invention provides the use of reagents for detecting the expression level of protein markers in the preparation of products for detecting radiotherapy sensitivity of pituitary adenomas, as well as kits and protein marker combinations for detecting radiotherapy sensitivity of pituitary adenomas . The present invention can detect the sensitivity of the treated object to radiotherapy of pituitary adenoma by detecting the expression level of protein markers, and analyze whether there is radiotherapy resistance, thereby providing an effective basis for predicting the effect of patients receiving radiotherapy and guiding clinical diagnosis and treatment.

The invention discloses an anti-tumor combined medicine which comprises a sugar medicine and a traditional Chinese medicine composition, wherein the sugar medicine is at least prepared from leprin acetylsugar, coprinus comatus polysaccharide and cellobiose; the weight ratio of the sugar medicine to the traditional Chinese medicine composition is 1: (2 to 5); the mass ratio of the leprin acetylsugar to the coprinus comatus polysaccharide to the cellobiose is 1: (4 to 6): (1 to 2). After the leprin acetylsugar, the coprinus comatus polysaccharide and the cellobiose in the anti-tumor combined medicine disclosed by the invention are cooperated with the traditional Chinese medicine composition at a specific ratio, a synergetic effect is achieved, and the disease resistance of a human body can be enhanced; under the action of enhancing the immune function, the defense mechanism in an organism is improved, reappear and transfer of a tumor are prevented, and an extremely good treating effect is achieved on the tumor; the anti-tumor combined medicine has effects of treating or preventing digestive system cancers, leukemia, pituitary adenoma, small cell lung carcinoma, cancerous goiter and astrocyte tumor and has good clinical application prospect.

The invention discloses a novel acromegaly screening system and a screening method thereof. The system comprises a pituitary adenoma intelligent health management platform, a hand feature database andan artificial intelligence early screening system; the pituitary adenoma intelligent health management platform is used for collecting hand photos of a to-be-tested person. the pituitary adenoma intelligent health management platform stores the collected hand photos in a hand feature database; the artificial intelligence early screening system comprises a convolutional neural network; the convolutional neural network carries out artificial intelligence deep learning on the hand photos in the hand feature database, so that a deep learning model is established, operation is carried out, and repeated verification and correction and data classification are carried out; and the artificial intelligence early screening system performs artificial intelligence background measurement and calculation on the hand photos, then outputs screening data, and preliminarily determines whether the patient is acromegaly patient or not according to the screening data; The novel acromegaly screening systemis low in cost and high in efficiency, replaces hematology / nuclear magnetic resonance examination and the like, and effectively reduces investment of manpower and material resources for screening.

The invention discloses use of brusatol and analogues thereof or pharmaceutically acceptable salts thereof in preparing medicines for treating pituitary adenoma. Different from a classic approach of promoting tumor cell apoptosis by DRD2 dependence of a dopamine receptor agonist, the brusatol and analogues thereof achieve inhibition effects of medicine on pituitary adenoma such as prolactinoma, clinical non-functional pituitary adenoma and growth hormone adenoma by promoting cells to generate ROS to induce cell apoptosis.

The invention relates to the technical field of medical appliances, and discloses a basis cranii repairing device for resection of pituitary adenoma via sphenoid sinus. The device comprises a first plug disc and a lumbar support formed on the first side of the first plug disc, wherein the first plug disc and the lumbar support have metal reticular structures; the second side surface of the first plug disc is coated with a first flexible blocking layer; the first flexible blocking layer is larger than the first plug disc, and the periphery of the first flexible blocking layer extends out of the edge of the first plug disc. The basis cranii repairing device can be used for effectively repairing the skull defect after repairing operation due to the first plug disc and the first flexible blocking layer, cerebrospinal fluid leakage is prevented, and infection rate is reduced.

The invention discloses an application of an estrogen receptor related receptor gamma (ESRRG) variant transcript in auxiliary diagnosis of pituitary adenoma, especially in auxiliary diagnosis of prolactin pituitary adenoma. By detecting whether the ESRRG transcript has an abnormal transcript or not and developing and applying the diagnostic kit, the pituitary adenoma, especially prolactin pituitary adenoma, can be more conveniently and easily diagnosed, so that a patient can know the disease risk in the early stage of the disease, a simple and effective auxiliary means is provided for drug screening, drug effect evaluation and targeted therapy of prolactin pituitary adenoma, especially prolactin pituitary adenoma.

The invention provides a nonfunctional pituitary adenoma detection device and application thereof. The device is used for carrying out Massarray SNP parting detection on a mononucleotide polymorphic site rs2981582 of a sample to be detected; the site has significant correlation with the attack of the nonfunctional pituitary adenoma; different genetic models of the site can provide certain basis for diagnosis of the nonfunctional pituitary adenoma and have higher clinical values. Through the nonfunctional pituitary adenoma detection device and the application thereof, a simple and reliable diagnosis method is provided for early diagnosis of patients with nonfunctional pituitary adenoma.

The invention provides a method for identifying a human growth hormone protein existence form biomarker spectrum, which comprises the following steps: collecting human growth hormone secreting pituitary adenoma and normal pituitary tissue samples, respectively extracting tissue proteins, carrying out two-way gel electrophoresis, western blot and coomassie brilliant blue staining, scanning a visual PVDF membrane and a two-way gel into a digital image, digesting corresponding two-way gel protein spots with trypsin, purifying, and identifying a GHP biomarker spectrum through mass spectrum identification and bioinformatics analysis; and identifying post-translational modifications and shear variations on GHP by using quantitative phosphorylated proteomics, ubiquitinated proteomics, and acetylated proteomics analysis in combination with bioinformatics. According to the invention, the GHP change mode between the growth hormone secreting pituitary adenoma and normal pituitary tissues can be identified, 46 kinds of GHPs are identified in the growth hormone secreting pituitary adenoma, 35 kinds of GHPs are identified in the normal pituitary tissues, and 11 kinds of GHPs only appear in the growth hormone secreting pituitary adenoma tissues.

The invention discloses application of circRNA-PTN to pituitary adenoma biomarkers, and particularly relates to the technical field of purposes of natural ribonucleotide. The length of the circRNA-PTNis 452bp; the circRNA-PTN is positioned on 137254974 to 137251230 on a 7th chromosome of a human body; PTN is a covering gene of the circRNA; the circRNA-PTN is formed by fourth, fifth and sixth exons of the PTN through trans-splicing; the quantity of the circRNA-PTN from a pituitary adenoma tissue sample of an object is detected; the lower-quantity circRNA-PTN has high pituitary adenoma invasiveness and is relevant to the bad prognosis possibility increase of the object. The purpose of the circRNA-PTN is provided. The circRNA-PTN has the application prospects of becoming the pituitary adenoma biomarkers.

The invention discloses a gene combination for distinguishing non-invasive and invasive non-functional pituitary adenomas. The gene combination consists of the following genes of INSM1, Jun, JunB, RHOU, RHOB, EZR, LLGL2, SNX33, SPIRE2, MLF1, HSPA2, CDKN1A, ERN1, NR2F2, GAS2, CDK6, SFRP1, EMILIN2, CD9 and SEMA7A. By detecting the expression level of the gene combination, the non-invasive and invasive non-functional pituitary adenomas can be distinguished.

The invention relates to a pituitary adenoma operation patch and a producing method thereof. The patch is filled at a skull base bone defect opening of pituitary adenoma operation, and the edge shape of the patch is matched with the edge shape of the bone defect opening; the patch is a piece made of a PCL-TCP material. The producing method of the patch comprises the following steps: performing data processing by virtue of computer image processing and three-dimensional substantive design software, and performing 3D printing to produce the patch. The pituitary adenoma operation patch has the beneficial effects that the advantages of a computer image processing technique is utilized, the pituitary adenoma operation patch is produced by combining the novel material PCL-TCP with the 3D printing technique, and then the bone defect is repaired. The pituitary adenoma operation patch is high in producing speed, high in structural property, excellent in biological property, high in precision and high in repair tightness, the surgery cost can be reduced, the operation time is shortened, the postoperative complications are reduced, the operative wound is alleviated, postoperative recovery is promoted, and the benefits of patients are maintained.

Spiroindoline derivatives, processes for their preparation and pharmaceutical compositions thereof, their use for the treatment of diseases, and their use for the manufacture of medicaments for the treatment of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selected from the group of endometriosis, uterine leiomyoma (fibroids), polycystic ovarian disease, menorrhagia, dysmenorrhea, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception, infertility and assisted reproductive therapy such as in vitro fertilization. The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.

The invention provides application of USP48 gene mutation in ACTH type pituitary adenoma molecular diagnosis and particularly provides a specific gene mutation in body of a patient with ACTH type pituitary adenoma, i.e. USP48 gene mutation. Experiment results show that, through detection on the USP48 gene mutation, the patient with the ACTH type pituitary adenoma can be diagnosed, and a diagnosisbasis is provided for subsequent specific and targeted treatment. The invention also provides application of such mutation genes as a pituitary adenoma therapeutic target.